mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis
about
sameAs
Real-time monitoring of tumorigenesis, dissemination, & drug response in a preclinical model of lymphangioleiomyomatosis/tuberous sclerosis complexManagement of lymphangioleiomyomatosisClinical features, epidemiology, and therapy of lymphangioleiomyomatosisNon-canonical functions of the tuberous sclerosis complex-Rheb signalling axisUterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosisThe neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis.Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomyomatosis.Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapyLamstatin--a novel inhibitor of lymphangiogenesis derived from collagen IV"Universal" vitrification of cells by ultra-fast cooling.Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell StemnessmTOR Overactivation and Compromised Autophagy in the Pathogenesis of Pulmonary Fibrosis.Frequency of undiagnosed cystic lung disease in patients with sporadic renal angiomyolipomasTargeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM)Evidence Supporting a Lymphatic Endothelium Origin for Angiomyolipoma, a TSC2(-) Tumor Related to Lymphangioleiomyomatosis.Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor geneIntegration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis.Rapamycin: one drug, many effects.A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options.Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.Clinical utility gene card for: tuberous sclerosis complex (TSC1, TSC2).An Official American Thoracic Society Workshop Report: Translational Research in Rare Respiratory Diseases.Downregulation of PERK activity and eIF2α serine 51 phosphorylation by mTOR complex 1 elicits pro-oxidant and pro-death effects in tuberous sclerosis-deficient cells.The LAM Lung Cell and Its Human Cell Models.Immunohistological features related to functional impairment in lymphangioleiomyomatosis.
P2860
Q27301399-D1689463-545C-4298-868D-4DCF5B63896CQ28084725-9DDA6B6E-A511-4432-A15D-5C25D3A4C5E6Q28084975-23669159-2F04-4AEC-ADBC-BAF1BBF5D1C3Q28728348-F9A6B795-8CF7-455A-8ED7-1A97369CF380Q30411083-D18DCA88-218F-43B6-BE32-88FC219748B7Q34560457-3D704ADC-C3E6-473D-BDB5-BF2919C8FB72Q34569989-7F325048-707D-443F-A6D2-FFDE2CCCCD2FQ34924914-A37FBA0F-1046-442E-86AB-224D15852C49Q35074335-88C9EF5C-779F-4372-B26B-B67BAE5F9518Q35107703-81F02BAE-5FCC-489F-9D56-253C22924397Q35370419-1F6BAEE1-36B0-47FD-9A7A-929887DCFDF6Q35500444-56AAC84B-3F51-4EFD-8A78-FCAE72DDB836Q35689467-5C02CECC-E80A-41DB-919E-3A70680388A9Q35780096-A67D8D64-D068-4391-8D89-E3029D8977E9Q36411134-6C8822DF-11FD-4E87-B2EA-0A22FFF143A1Q36636671-5353AF2D-E399-4368-B2CD-7D8626BD2542Q37057152-A090FEA2-607C-4300-8127-72309C28AA2FQ37149062-75102477-8DEE-45DB-B837-8BA629C3E50AQ37173102-EB4BC7F8-4F44-4F70-A60E-321164F0FF84Q37679469-BF080C16-D547-40CE-AB00-73804D865EC8Q37937344-3F699382-D12F-4DE7-93EF-186FDB4EEE1DQ38895095-E4F3F092-0C12-4525-A2C0-03E4385F0D1EQ41878885-0B3E45FF-E824-4289-A65C-6B10B86E9A0CQ47815265-14F1031F-7538-4E38-880C-3F444F09DAFFQ49959221-10EDE654-3933-4D85-B9FC-8D241B104E48Q50181460-536D858A-2E47-4F34-9C38-39EFC6E4C3A2Q54979000-F64C17B4-59A2-4439-9507-7A5B48891F6D
P2860
mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
mTOR activation, lymphangiogen ...... ic factors in LAM pathogenesis
@ast
mTOR activation, lymphangiogen ...... ic factors in LAM pathogenesis
@en
mTOR activation, lymphangiogen ...... ic factors in LAM pathogenesis
@nl
type
label
mTOR activation, lymphangiogen ...... ic factors in LAM pathogenesis
@ast
mTOR activation, lymphangiogen ...... ic factors in LAM pathogenesis
@en
mTOR activation, lymphangiogen ...... ic factors in LAM pathogenesis
@nl
prefLabel
mTOR activation, lymphangiogen ...... ic factors in LAM pathogenesis
@ast
mTOR activation, lymphangiogen ...... ic factors in LAM pathogenesis
@en
mTOR activation, lymphangiogen ...... ic factors in LAM pathogenesis
@nl
P2860
P356
P1476
mTOR activation, lymphangiogen ...... ic factors in LAM pathogenesis
@en
P2093
Elizabeth Petri Henske
P2860
P356
10.1089/LRB.2009.0020
P407
P577
2010-03-01T00:00:00Z